Eli Lilly and Co. stock pre-market at EUR 1,021.50: plus 0.48 percent
Published on 10/05/2026 at 09:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Eli Lilly and Co. stock was at EUR 1,021.50 in pre-market trading on October 5, 2026, up 0.48 percent versus the Lang & Schwarz prior close of EUR 1,016.60 on October 2, 2026. The price data is from Lang & Schwarz. The further course from the Xetra open at 9:00 a.m. CEST is shown by the continuously updated real-time quote of Eli Lilly and Co. stock.
Jaypirca receives expanded FDA indication
On October 2, 2026, Eli Lilly and Company said the U.S. Food and Drug Administration had approved an additional indication for Jaypirca, or pirtobrutinib, in adults with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma without a known 17p deletion. The approval allows Jaypirca to be used as a first-line treatment for appropriate patients, according to Eli Lilly and Company.
Clinical-trial results cited
Lilly said the approval was based on the Phase 3 BRUIN CLL-313 study. At a median follow-up of 28 months, the company reported that progression-free survival was significantly improved with pirtobrutinib compared with bendamustine plus rituximab; median progression-free survival had not yet been reached for pirtobrutinib versus 33.5 months for the comparator. Lilly also reported an overall response rate of 94 percent for pirtobrutinib and 81 percent for bendamustine plus rituximab in the study, as detailed in the company release.
